The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Biovica
Stock and Other Ownership Interests - Biovica; Novartis
Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.
 
Erin Frances Cobain
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca/Daiichi Sankyo; Athenex; Ayala Pharmaceuticals; bioTheranostics; Immunomedics
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
William E. Barlow
Research Funding - AstraZeneca (Inst); Merck (Inst)
 
Costanza Paoletti
Employment - Eisai
 
Mattias Bergqvist
Employment - Biovica
Stock and Other Ownership Interests - Biovica
 
Amy Williams
No Relationships to Disclose
 
Hanna Ritzen
Employment - Biovica
Stock and Other Ownership Interests - Biovica
 
Rita S. Mehta
No Relationships to Disclose
 
Julie R. Gralow
Consulting or Advisory Role - Genentech; Roche
 
Gabriel N. Hortobagyi
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Novartis; Seagan
Research Funding - Novartis (Inst)
 
Kathy S. Albain
Honoraria - Encore Medical Education
Research Funding - Quantum Leap Healthcare Collaborative (Inst); Seagen (Inst)
Other Relationship - Seagen
 
Lajos Pusztai
Honoraria - Athenex; bioTheranostics; natera; OncoCyte
Consulting or Advisory Role - Almac Diagnostics; AstraZeneca; Bristol Myers Squibb; Clovis Oncology; Eisai; H3 Biomedicine; Immunomedics; Merck; Novartis; Pfizer; Roche/Genentech; Seagen; Syndax
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Foundation Medicine; NanoString Technologies
 
Priyanka Sharma
Stock and Other Ownership Interests - Amgen Astellas BioPharma (I)
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; GlaxoSmithKline; Merck; Novartis; Pfizer; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Gilead Sciences; Merck (Inst); Novartis; Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Andrew K. Godwin
Stock and Other Ownership Interests - Clara Biotech
Honoraria - Sinochips Kansas
Consulting or Advisory Role - Biovica
Research Funding - BioFluidica (Inst); Clara Biotech (Inst); Predicine (Inst); VITRAC Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Provisional Patent application entitled - "WJMSC-Derived Small Extracellular Vesicle (sEVs) Enhance T Cell Suppression Through Checkpoint PD-L1" - Dr. Joseph McGuirk (applicant) (Inst)
 
Alastair Mark Thompson
Employment - Lilly (I)
Stock and Other Ownership Interests - Lilly (I)
Travel, Accommodations, Expenses - Endomagnetics
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion
Honoraria - Tempus
Consulting or Advisory Role - BioVica; Cellworks; Cepheid; Epic Sciences; Exact Sciences; Freenome; Guardant Health; L-Nutra; Macrogenics; Oncocyte; Predictus Biosciences; Tempus; Turnstone Bio; xilis
Research Funding - AstraZeneca (Inst); Cepheid/Danaher (Inst); Menarini Silicon Biosystems (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Other Relationship - Menarini; UpToDate
(OPTIONAL) Uncompensated Relationships - UpToDate
 
James M. Rae
No Relationships to Disclose